TNFRSF17 and lymphoma: Using 3rd-generation CARs, which outperform 2nd-generation CARs in clinical outcomes,58,59 we demonstrated enhanced anti-tumor activity in lymphoma, leukemia, multiple myeloma (BCMA targeting), and brain cancer (SH-S5Y5 targeting) models.